Beth Bioinformatics

Beth Bioinformatics develops advanced AI-driven bioinformatic platforms to empower pharmaceutical companies in designing more effective vaccines and improving precision medicine. Their solutions include virus evolution prediction models, real-time in-silico vaccine effectiveness estimation, epitope screening/antigen design tools, codon optimization technologies for improved expression/immunogenicity of antigens, and omics-based analytics for complex disease risk assessment. The company collaborates with multiple pharmaceutical partners on new vaccine development projects targeting viruses such as Influenza and SARS-CoV‑2. They have also pioneered methods to predict influenza vaccine effectiveness by sequence analysis before vaccination occurs—enabling rapid response to emerging viral variants—and offer region-specific antigen designs that can improve existing flu vaccines’ efficacy by 20–40%. Additionally, they provide early screening services for complex diseases using human genome data combined with machine learning approaches.